JP2004519452A5 - - Google Patents

Download PDF

Info

Publication number
JP2004519452A5
JP2004519452A5 JP2002554133A JP2002554133A JP2004519452A5 JP 2004519452 A5 JP2004519452 A5 JP 2004519452A5 JP 2002554133 A JP2002554133 A JP 2002554133A JP 2002554133 A JP2002554133 A JP 2002554133A JP 2004519452 A5 JP2004519452 A5 JP 2004519452A5
Authority
JP
Japan
Prior art keywords
vaccine
use according
antigen
compound
polycationic compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002554133A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004519452A (ja
Filing date
Publication date
Priority claimed from PCT/EP2001/000087 external-priority patent/WO2001054720A1/en
Application filed filed Critical
Priority claimed from PCT/EP2002/000062 external-priority patent/WO2002053184A2/en
Publication of JP2004519452A publication Critical patent/JP2004519452A/ja
Publication of JP2004519452A5 publication Critical patent/JP2004519452A5/ja
Pending legal-status Critical Current

Links

JP2002554133A 2001-01-05 2002-01-07 ポリカチオン性化合物の用途 Pending JP2004519452A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2001/000087 WO2001054720A1 (en) 2000-01-28 2001-01-05 Pharmaceutical composition for immunomodulation and preparation of vaccines comprising an antigen and an immunogenic oligodeoxynucleotide and a polycationic polymer as adjuvants
AT6722001 2001-04-25
PCT/EP2002/000062 WO2002053184A2 (en) 2001-01-05 2002-01-07 Uses for polycationic compounds as vaccine adjuvants

Publications (2)

Publication Number Publication Date
JP2004519452A JP2004519452A (ja) 2004-07-02
JP2004519452A5 true JP2004519452A5 (enExample) 2005-12-22

Family

ID=25608382

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002554133A Pending JP2004519452A (ja) 2001-01-05 2002-01-07 ポリカチオン性化合物の用途

Country Status (4)

Country Link
EP (1) EP1347775B1 (enExample)
JP (1) JP2004519452A (enExample)
CA (1) CA2433794A1 (enExample)
WO (1) WO2002053184A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1347775B1 (en) 2001-01-05 2016-11-30 Valneva Austria GmbH Uses for polycationic compounds as vaccine adjuvants
EP1608402B1 (en) * 2003-03-24 2010-10-20 Intercell AG Improved vaccines
WO2011101465A1 (en) 2010-02-19 2011-08-25 Intercell Ag Ic31 nanoparticles
KR101586200B1 (ko) * 2014-12-31 2016-01-18 성균관대학교산학협력단 면역자극 조성물, 이의 제조 방법, 및 이를 포함하는 면역요법 조성물
US20230210763A1 (en) * 2019-09-19 2023-07-06 Amw Gmbh Extruded depot form for controlled active substance release

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB744988A (en) * 1952-01-31 1956-02-15 Allen & Hanburys Ltd Improvements in preparations of insulin
GB8921470D0 (en) * 1989-09-22 1989-11-08 Peptide Technology Ltd Vaccines
AU653771B2 (en) * 1991-01-03 1994-10-13 Alkermes Controlled Therapeutics, Inc. Stabilization of proteins by cationic biopolymers
CO4600681A1 (es) * 1996-02-24 1998-05-08 Boehringer Ingelheim Pharma Composicion farmaceutica para la modulacion inmunitaria
DE60003151T2 (de) * 1999-01-13 2004-04-08 Johns Hopkins University School Of Medicine Genetische immunisierung mit gleichzeitiger verabreichung von nukleinsäuren und zytokinen
PL203951B1 (pl) * 1999-04-19 2009-11-30 Smithkline Beecham Biolog Kompozycja adiuwantowa, kompozycja szczepionki oraz sposób jej wytwarzania, szczepionka oraz zastosowanie
AT408721B (de) * 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
AT409085B (de) 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
HU228264B1 (en) * 2000-06-08 2013-02-28 Intercell Ag Immunostimulatory oligodeoxynucleotides
AT410635B (de) * 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
EP1347775B1 (en) 2001-01-05 2016-11-30 Valneva Austria GmbH Uses for polycationic compounds as vaccine adjuvants

Similar Documents

Publication Publication Date Title
JP2003526662A5 (enExample)
García et al. An overview of adjuvant formulations and delivery systems
WO2000062800A3 (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
JP2003535043A5 (enExample)
MX353044B (es) Liberacion sostenida de anti-infecciosos.
EA200501420A1 (ru) Устройство доставки для лекарственной и клеточной терапии
CY1110140T1 (el) Εμβολιασμος με μηνιγγοκοκκικο συζευγμα
JP2003528155A5 (enExample)
JP2005519985A5 (enExample)
WO2002034205A3 (en) Using heat shock proteins to increase immune response
JP2003506416A5 (enExample)
JP2003513935A5 (enExample)
JP2006506441A5 (enExample)
JP2002531521A5 (enExample)
JP2002542204A5 (enExample)
JP2006513184A5 (enExample)
JP2002534481A5 (enExample)
WO2002032378A3 (en) Fusion cells and cytokine compositions for treatment of disease
JP2004519452A5 (enExample)
WO2001095934A3 (en) The use of plant oil-bodies in vaccine delivery systems
JP2003514025A5 (enExample)
WO2000062802A3 (en) Vaccine comprising rsv antigen and cpg oligonucleotide
JP2004519453A5 (enExample)
EP1905449A3 (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
RU2009142690A (ru) Режим вакцинации для в-клеточной вакцины